<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927118</url>
  </required_header>
  <id_info>
    <org_study_id>BulentEU2</org_study_id>
    <nct_id>NCT03927118</nct_id>
  </id_info>
  <brief_title>Effect of Dexamethasone Implant on Optic Disc</brief_title>
  <official_title>The Effect of Dexamethasone Implant on Retinal Nerve Fiber and Optic Disc Morphology in Patients With Diabetic Maculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bulent Ecevit University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bulent Ecevit University</source>
  <brief_summary>
    <textblock>
      This study evaluates the effect of dexamethasone implant which is an intraocular
      corticosteroid on the optic nerve fibers. Retinal nerve fiber thicknesses and optic nerve
      head pitting rates were measured before and 6 months after the injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic macular edema is the most frequent ocular complication of diabetes resulting in
      irreversible loss of vision if untreated. Dexamethasone implant implant is used to treat
      macular edema due to diabetes. It stay in the vitreous for 6 months after intravitreal
      administration.

      Dexamethasone implant can lead to retinal nerve fiber layer and optic nerve damage by both
      increasing intraocular pressure and its direct effect on neural tissue during the effective
      6-month period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peripapillary RNFL thickness measurements</measure>
    <time_frame>six month</time_frame>
    <description>micrometer</description>
  </primary_outcome>
  <enrollment type="Actual">43</enrollment>
  <condition>Glaucoma and Ocular Hypertension</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Intravenous Drug Usage</condition>
  <condition>Optic Disk Disorders</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravitreal dexamethasone implant application</intervention_name>
    <description>Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.</description>
    <other_name>The Effect of Dexamethasone Implant on Retinal Nerve Fiber and Optic Disc in Diabetic maculopathy.</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic patient group will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients who underwent first time intravitreal injection

        Exclusion Criteria

        Previously received any surgery

        Proliferative diabetic retinopathy

        Glaucoma or glaucoma suspicion

        Optic disc fatigue

        Optic disc edema

        Uveitis and media opacity

        Blurred of image clarity
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Individuals over 20 years of age were included in the study.</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atilla Alpay, Ass. Prf.</last_name>
    <role>Study Director</role>
    <affiliation>Zonguldak Bulent Ecevit University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zonguldak Bülent Ecevit Üniversitesi.</name>
      <address>
        <city>Zonguldak</city>
        <state>Kozlu</state>
        <zip>67600</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Du JH, Li X, Li R, Xu L, Ma RR, Liu SF, Zhang Z, Sun HZ. Elevation of serum apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients. Int J Ophthalmol. 2014 Dec 18;7(6):968-73. doi: 10.3980/j.issn.2222-3959.2014.06.10. eCollection 2014.</citation>
    <PMID>25540748</PMID>
  </reference>
  <reference>
    <citation>Liu L, Wu X, Liu L, Geng J, Yuan Z, Shan Z, Chen L. Prevalence of diabetic retinopathy in mainland China: a meta-analysis. PLoS One. 2012;7(9):e45264. doi: 10.1371/journal.pone.0045264. Epub 2012 Sep 20.</citation>
    <PMID>23028893</PMID>
  </reference>
  <reference>
    <citation>Assmann TS, Brondani LA, Bouças AP, Rheinheimer J, de Souza BM, Canani LH, Bauer AC, Crispim D. Nitric oxide levels in patients with diabetes mellitus: A systematic review and meta-analysis. Nitric Oxide. 2016 Dec 30;61:1-9. doi: 10.1016/j.niox.2016.09.009. Epub 2016 Sep 24. Review.</citation>
    <PMID>27677584</PMID>
  </reference>
  <reference>
    <citation>Suwanpradid J, Rojas M, Behzadian MA, Caldwell RW, Caldwell RB. Arginase 2 deficiency prevents oxidative stress and limits hyperoxia-induced retinal vascular degeneration. PLoS One. 2014 Nov 6;9(11):e110604. doi: 10.1371/journal.pone.0110604. eCollection 2014.</citation>
    <PMID>25375125</PMID>
  </reference>
  <reference>
    <citation>Celik M, Cerrah S, Arabul M, Akalin A. Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients. J Diabetes Res. 2014;2014:139215. doi: 10.1155/2014/139215. Epub 2014 Apr 3.</citation>
    <PMID>24804267</PMID>
  </reference>
  <reference>
    <citation>Lluch P, Segarra G, Medina P. Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. World J Gastroenterol. 2015 Aug 28;21(32):9466-75. doi: 10.3748/wjg.v21.i32.9466. Review.</citation>
    <PMID>26327755</PMID>
  </reference>
  <reference>
    <citation>Heunisch F, Chaykovska L, von Einem G, Alter M, Dschietzig T, Kretschmer A, Kellner KH, Hocher B. ADMA predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus undergoing coronary angiography. Medicine (Baltimore). 2017 Feb;96(6):e6065. doi: 10.1097/MD.0000000000006065.</citation>
    <PMID>28178159</PMID>
  </reference>
  <reference>
    <citation>Franceschelli S, Ferrone A, Pesce M, Riccioni G, Speranza L. Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease. Int J Mol Sci. 2013 Dec 16;14(12):24412-21. doi: 10.3390/ijms141224412.</citation>
    <PMID>24351825</PMID>
  </reference>
  <reference>
    <citation>Yin YL, Zhu ML, Wan J, Zhang C, Pan GP, Lu JX, Ping S, Chen Y, Zhao FR, Yu HY, Guo T, Jian X, Liu LY, Zhang JN, Wan GR, Wang SX, Li P. Traditional Chinese medicine xin-mai-jia recouples endothelial nitric oxide synthase to prevent atherosclerosis in vivo. Sci Rep. 2017 Mar 2;7:43508. doi: 10.1038/srep43508.</citation>
    <PMID>28252100</PMID>
  </reference>
  <reference>
    <citation>Marcovecchio ML, Widmer B, Turner C, Dunger DB, Dalton RN. Asymmetric dimethylarginine in young people with Type 1 diabetes: a paradoxical association with HbA(1c). Diabet Med. 2011 Jun;28(6):685-91. doi: 10.1111/j.1464-5491.2011.03252.x.</citation>
    <PMID>21294768</PMID>
  </reference>
  <reference>
    <citation>Ersoy B, Eroğlu N, Çetin M, Onur E, Özkol M, Coşkun Ş. Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes. Diab Vasc Dis Res. 2018 May;15(3):196-203. doi: 10.1177/1479164118757921. Epub 2018 Mar 2.</citation>
    <PMID>29498294</PMID>
  </reference>
  <reference>
    <citation>Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002 Aug 20;106(8):987-92.</citation>
    <PMID>12186805</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bulent Ecevit University</investigator_affiliation>
    <investigator_full_name>Atilla Alpay</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Diabetic maculopathy</keyword>
  <keyword>dexamethasone implant</keyword>
  <keyword>optic disc</keyword>
  <keyword>vascular endothelial growth factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

